Olema Pharmaceuticals, Inc.
OLMA
$27.41
$0.260.94%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.12% | -6.74% | 0.19% | -5.74% | -0.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.21% | 23.19% | 32.83% | 30.77% | 35.11% |
| Operating Income | -16.21% | -23.19% | -32.83% | -30.77% | -35.11% |
| Income Before Tax | -22.24% | -29.80% | -29.75% | -33.95% | -27.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.24% | -29.80% | -29.75% | -33.95% | -27.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.24% | -29.80% | -29.75% | -33.95% | -27.71% |
| EBIT | -16.21% | -23.19% | -32.83% | -30.77% | -35.11% |
| EBITDA | -16.22% | -23.17% | -32.88% | -30.87% | -35.26% |
| EPS Basic | 14.56% | 4.00% | 0.42% | -2.29% | 5.80% |
| Normalized Basic EPS | 18.46% | 7.92% | -1.54% | 1.02% | 4.61% |
| EPS Diluted | 14.56% | 4.00% | 0.42% | -2.29% | 5.80% |
| Normalized Diluted EPS | 18.46% | 7.92% | -1.54% | 1.02% | 4.61% |
| Average Basic Shares Outstanding | 44.01% | 38.92% | 35.05% | 29.90% | 34.69% |
| Average Diluted Shares Outstanding | 44.01% | 38.92% | 35.05% | 29.90% | 34.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |